More than 3 million Americans have inherited bleeding disorders, and social determinants of health (SDOH) play a role in a number of ways, including cost for treatment, difficulty accessing specialists, educational barriers, and more.
A recent review examined the impact of social determinants of health (SDOH) on health outcomes for individuals with inherited bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand disease, and others.
More than 3 million Americans have such disorders, and social determinants play a role in a number of ways, including cost for treatment, difficulty accessing specialists, educational barriers, and more.
The authors used PubMed to search for articles published in English between 2011 and 2021. Inclusion criteria included studies in which 1 of the following clinical outcomes were measured: bleeding frequency, chronic pain, mortality, quality of life, and/or cost of treatment, in a population diagnosed with an inherited bleeding disorder. In addition, results were restricted to free text articles.
The search resulted in 1466 original articles, and 13 articles were chosen for the analysis. Articles were categorized by categories of SDOH: health care system, economic stability, neighborhood/physical environment, community/social context, education, and food.
Several of the 13 articles overlapped multiple areas: 3 were categorized as economic stability, 1 was categorized as neighborhood and physical environment, 2 were categorized as education, 12 were categorized as community and social context, and 4 were categorized as health care systems. None fell into the food category.
The following themes were identified from the reports, which included case studies, literature reviews, and cross-sectional studies:
The analysis had several limitations, including the fact that the search was limited to free full-text English articles due to funding issues, and so there may be publication bias. The SDOH category of food was not analyzed in the results. Finally, most studies were observational designs.
The authors called for additional research, including studies that delve more deeply into specific areas of SDOH impact, such as food and neighborhoods.
Reference
Lopez K, Norris K, Hardy M, Valentino L. Defining the impact of social drivers on health outcomes for people with inherited bleeding disorders. J Clin Med. Published online July 30, 2022. doi:10.3390/jcm11154443
Study Reveals Racial Disparities in Immune Tolerance Induction Treatment for Hemophilia
November 14th 2023New research highlights racial disparities in hemophilia care, revealing that Black and Hispanic patients are significantly less likely to receive immune tolerance induction treatment compared with White patients, even after considering clinical factors.
Read More
Etranacogene Dezaparvovec Gene Therapy Outperforms FIX Products in Hemophilia B
November 1st 2023The findings from a recent study unveiled notable distinctions in bleeding rates between etranacogene dezaparvovec and the standard prophylactic factor IX (FIX) products among individuals diagnosed with hemophilia B.
Read More
Study Identifies Core Instruments for Monitoring Physical Function in Hemophilia
October 28th 2023The study identified practical instruments for monitoring physical function in people with hemophilia by pinpointing 11 potential markers and establishing performance-based tests for 5 of these activities.
Read More
ANNEXA-I: Andexanet Alfa Shows Efficacy, Safety for Factor Xa Reversal in Acute ICH
October 27th 2023The phase 4 ANNEXA-I trial was stopped early after showing superior hemostatic efficacy and the capability to limit potentially life-threatening intracerebral hemorrhage (ICH) compared with usual care in patients taking oral factor Xa (FXa) inhibitors.
Read More
Damoctocog Alfa Pegol Demonstrates Safety and Efficacy in Hemophilia A
October 26th 2023While clinical trials offer controlled data, real-world studies like HEM-POWR bridge gaps, confirming damoctocog alfa pegol’s effectiveness and tolerance, establishing it as a valuable hemophilia A treatment option.
Read More